Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20781286 | 0.91 | KMT2A (0.51) | ALDH1A1YAP1KMT2AMEN1NPSR1 | |
| SCHEMBL20415563 | 0.89 | CMA1 (0.51) | CMA1ACE | |
| SCHEMBL30487497 | 0.87 | CTRB1 (0.54) | ALDH1A1YAP1KMT2AMEN1NPSR1 | |
| SCHEMBL18374556 | 0.86 | CMA1 (0.44) | YAP1FAPCMA1 | |
| SCHEMBL18374383 | 0.85 | OPRM1 (0.50) | — | |
| SCHEMBL30487494 | 0.85 | CMA1 (0.54) | ALDH1A1YAP1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18609373 | 0.83 | ALDH1A1 (0.55) | ALDH1A1YAP1KMT2AMEN1NPSR1 | |
| SCHEMBL18577421 | 0.83 | ALDH1A1 (0.55) | ALDH1A1YAP1KMT2AMEN1NPSR1 | |
| SCHEMBL18577419 | 0.83 | ALDH1A1 (0.55) | ALDH1A1YAP1KMT2AMEN1NPSR1 | |
| SCHEMBL18577417 | 0.83 | ALDH1A1 (0.55) | ALDH1A1YAP1KMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-06-21 | — | — | US | disclosed |
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-07-26 | — | — | US | disclosed |
| WO-2017008033-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Reasearch & Business Foundation Sungkyunkwan University (KR) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008924-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208625-A1 | METHOD FOR PREVENTING, IMPROVING, OR TREATING INFLAMMATORY BOWEL DISEASE | SI, NOD2, TNF | ALDH1A1 873/4885YAP1 1249/4885KMT2A 4521/4885 |
| US-20170008924-A1 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | NOD2, SI, APC | ALDH1A1 2316/4885YAP1 2657/4885KMT2A 3249/4885 |
| US-11365215-B2 | Method for preventing, improving, or treating inflammatory bowel disease | SI, NOD2, TNF | ALDH1A1 873/4885YAP1 1249/4885KMT2A 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.